The Insider and Executive Chairman of TechTarget, Inc. (TTGT), Greg Strakosch, Unloaded 25,000 Shares; Biotime Has 2.62 Sentiment

TechTarget, Inc. (NASDAQ:TTGT) Logo

Sentiment for Biotime Inc (BTX)

Biotime Inc (BTX) investors sentiment increased to 2.62 in 2017 Q4. It’s up 0.66, from 1.96 in 2017Q3. The ratio has improved, as 55 investment managers opened new and increased stock positions, while 21 sold and reduced their positions in Biotime Inc. The investment managers in our database now hold: 57.90 million shares, up from 49.13 million shares in 2017Q3. Also, the number of investment managers holding Biotime Inc in top ten stock positions was flat from 2 to 2 for the same number . Sold All: 5 Reduced: 16 Increased: 34 New Position: 21.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $281.65 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It currently has negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

Broadwood Capital Inc holds 8.98% of its portfolio in BioTime, Inc. for 29.97 million shares. Manatuck Hill Partners Llc owns 351,822 shares or 0.39% of their US portfolio. Moreover, Dafna Capital Management Llc has 0.32% invested in the company for 275,000 shares. The Florida-based Prescott General Partners Llc has invested 0.17% in the stock. Berson & Corrado Investment Advisors Llc, a New York-based fund reported 74,875 shares.

The stock decreased 2.63% or $0.06 during the last trading session, reaching $2.22. About 348,793 shares traded. BioTime, Inc. (BTX) has declined 25.77% since April 26, 2017 and is downtrending. It has underperformed by 37.32% the S&P500.

Analysts await BioTime, Inc. (NYSEAMERICAN:BTX) to report earnings on May, 9. They expect $-0.08 EPS, 0.00% or $0.00 from last year’s $-0.08 per share. After $-0.08 actual EPS reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

The stock decreased 0.15% or $0.03 during the last trading session, reaching $20.64. About 140,874 shares traded. TechTarget, Inc. (NASDAQ:TTGT) has risen 118.72% since April 26, 2017 and is uptrending. It has outperformed by 107.17% the S&P500.

Investors sentiment decreased to 1.52 in Q4 2017. Its down 0.27, from 1.79 in 2017Q3. It dived, as 6 investors sold TechTarget, Inc. shares while 19 reduced holdings. 15 funds opened positions while 23 raised stakes. 12.38 million shares or 0.51% more from 12.31 million shares in 2017Q3 were reported. Hillsdale Invest Mngmt owns 91,210 shares. Macquarie Group Incorporated Ltd invested 0% in TechTarget, Inc. (NASDAQ:TTGT). Moreover, Ameritas Inv Prtnrs Incorporated has 0% invested in TechTarget, Inc. (NASDAQ:TTGT). Parallax Volatility Advisers L P has invested 0% of its portfolio in TechTarget, Inc. (NASDAQ:TTGT). 20,000 were reported by Alliancebernstein L P. California State Teachers Retirement System holds 0% or 30,908 shares. Hcsf Management Lc reported 15.45% stake. Arrowstreet Partnership has invested 0% of its portfolio in TechTarget, Inc. (NASDAQ:TTGT). The New York-based D E Shaw And has invested 0% in TechTarget, Inc. (NASDAQ:TTGT). The Connecticut-based Mark Sheptoff Planning Ltd Llc has invested 0% in TechTarget, Inc. (NASDAQ:TTGT). 16,845 are held by First Quadrant Limited Partnership Ca. Ariel Ltd Co reported 730,560 shares. Amer Int Group Incorporated Inc has invested 0% of its portfolio in TechTarget, Inc. (NASDAQ:TTGT). Moreover, Barclays Public Ltd Co has 0% invested in TechTarget, Inc. (NASDAQ:TTGT) for 12,912 shares. Royal Bank & Trust Of Canada stated it has 16 shares.

Since December 11, 2017, it had 0 insider buys, and 20 selling transactions for $7.46 million activity. Beam Kevin sold 10,000 shares worth $172,650. The insider Strakosch Greg sold $561,400. 20,000 shares were sold by Hawk Don, worth $390,027 on Friday, April 13. $469,072 worth of TechTarget, Inc. (NASDAQ:TTGT) was sold by Cotoia Michael. 30,000 shares were sold by MARINO ROGER M, worth $587,000. Nine Ten Partners LP sold $846,200 worth of stock or 55,000 shares. Noreck Daniel T had sold 2,000 shares worth $38,840 on Monday, April 16.

Analysts await TechTarget, Inc. (NASDAQ:TTGT) to report earnings on May, 9 after the close. TTGT’s profit will be $1.10M for 129.00 P/E if the $0.04 EPS becomes a reality. After $0.12 actual earnings per share reported by TechTarget, Inc. for the previous quarter, Wall Street now forecasts -66.67% negative EPS growth.

TechTarget, Inc. provides specialized online content for buyers of corporate information technology services and products; and purchase-intent marketing and sales services for enterprise technology vendors in the United States and internationally. The company has market cap of $567.26 million. It offers customized marketing programs that integrate demand generation and brand marketing, as well as advertising techniques, which enable IT vendors to identify, reach, and influence corporate IT decision makers who are researching specific IT purchases. It has a 86 P/E ratio. The companyÂ’s products include IT deal alert, core online, demand solutions, brand solutions, and custom content creation, which are provided through online, as well as operates face-to-face events.

TechTarget, Inc. (NASDAQ:TTGT) Institutional Positions Chart